Covid-19

Eye
#Clinical trials #Comment #Covid-19 #Eye #Eye health #Ophthalmology

New narrated podcast on ophthalmology

This is the latest episode of the free DDW podcast, “A deep dive into the future of ophthalmology”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Innovation, investment and commitment: Genentech’s approach to the future of ophthalmology” and “… Read More

#News

Year change from 2022 to 2023
#Clinical trial #Clinical trial design #Covid-19 #Drug delivery #Drug development #Healthcare

Drug discovery predictions: Analysis and insight 

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically on Anita Cooper’s prediction relating to… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

Listen to the first DDW Highlights podcast for 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with… Read More

#News

#Cancer immunotherapy #Cancer research #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies

This week in drug discovery (2-6 January)

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers. … Read More

#News

Antibodies attack Covid-19
#AstraZeneca #Covid-19 #Covid-19 treatment #Immunity #Monoclonal antibodies

Accelerated development for Covid-19 monoclonal antibody

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery.  AstraZeneca has initiated the SUPERNOVA Phase I/III trial of AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prophylaxis of Covid-19, following the company licensing AZD3152 from… Read More

#Covid-19 #News #Trending News

#Biologics / Biotechnology #Cell and gene therapy #Covid-19 #Drug discovery #mRNA-based vaccines #Plant-based #Synthetic biology #Ukraine

DDW’s best of 2022: What were your top reads?

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most… Read More

#Editor's Choice #Exclusive Content #News

#Clinical trials #Covid-19 #Data #Disease surveillance #Global.health #Immunology / Virology & Vaccines

Fortifying vaccines through disease surveillance and data reporting  

Shelley McLendon, SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. There, McLendon spoke on the topic of fortifying vaccines against future pandemics, specifically discussing: The importance of disease surveillance and reporting with regard to emerging… Read More

#Exclusive Content

Baby on a respirator - RSV
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Covid-19 #Immunology / Virology & Vaccines #Influenza #OneThree #Poolbeg Pharma #Respiratory syncytial virus

AI identifies drug candidates for respiratory syncytial virus

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV.  The AI programme, part of a collaboration between Poolbeg Pharma and OneThree, uses Poolbeg’s RSV human challenge… Read More

#Editor's Choice #News

#AstraZeneca #Biobanking #Covid-19 #Genetics #Genomics #Public health #Research

Podcast: Is genomic data the new frontier in drug discovery?

This is the latest episode of the free narrated DDW podcast, “Is genomic data the new frontier in drug discovery?” It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Genomics boosts understanding of Covid-19 severity and susceptibility” and “… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19 #Drug development #Healthcare #Public health #Regulatory

Drug development practices to improve public health policy 

Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this;… Read More

#Exclusive Content #Opinion #Regulatory

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

#Antibiotics #Antimicrobial resistance (AMR) #Cancer #Cancer research #Cell therapy #Covid-19 #Drug discovery #Oncology

Five key news stories available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week started with World Diabetes Day on 14 November and concluded… Read More

#News

#Antibiotics #Antimicrobial resistance (AMR) #Cancer #Cancer research #Cell therapy #Covid-19 #Drug discovery #Oncology

This week in drug discovery (14-18 November)

News round-up for 14-18 November by DDW Digital Content Editor Diana Spencer.  This week started with World Diabetes Day on 14 November and concluded with the start of World Antimicrobial Awareness Week, which aims to improve education and understanding of the growing issue of antimicrobial resistance. … Read More

#News

#Antibiotic resistance #Antimicrobial resistance (AMR) #Covid-19 #Drug discovery

AMR: why we need to advance the discovery of new antimicrobials

World Antimicrobial Awareness Week highlights the fact that antimicrobials have formed the bedrock of modern medicine, making surgeries, cancer care and treatments for life-threatening infections possible and improving human health in the process.  For years now, experts have laboured against the rise of antimicrobial resistance (AMR), urging governments to put… Read More

#Exclusive Content